Medline ® Abstract for Reference 6
of 'Toxicities associated with checkpoint inhibitor immunotherapy'
The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma.
Del Castillo M, Romero FA, Argüello E, Kyi C, Postow MA, Redelman-Sidi G
Clin Infect Dis. 2016;63(11):1490. Epub 2016 Aug 7.
The risk of infection among patients receiving immune checkpoint blockade is unknown. We retrospectively reviewed medical records of 740 patients with melanoma who received immune checkpoint blockers. Serious infection occurred in 54 patients (7.3%). The main risk factors were receipt of corticosteroids and/or infliximab.
Department of Medicine, Jacobi Medical Center, Bronx.